» Articles » PMID: 25333921

Ethyl Pyruvate Inhibits HMGB1 Phosphorylation and Release by Chelating Calcium

Overview
Journal Mol Med
Publisher Biomed Central
Date 2014 Oct 22
PMID 25333921
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Ethyl pyruvate (EP), a simple aliphatic ester of pyruvic acid, has been shown to have antiinflammatory effects and to confer protective effects in various pathological conditions. Recently, a number of studies have reported EP inhibits high mobility group box 1 (HMGB1) secretion and suggest this might contribute to its antiinflammatory effect. Since EP is used in a calcium-containing balanced salt solution (Ringer solution), we wondered if EP directly chelates Ca(2+) and if it is related to the EP-mediated suppression of HMGB1 release. Calcium imaging assays revealed that EP significantly and dose-dependently suppressed high K(+)-induced transient [Ca(2+)]i surges in primary cortical neurons and, similarly, fluorometric assays showed that EP directly scavenges Ca(2+) as the peak of fluorescence emission intensities of Mag-Fura-2 (a low-affinity Ca(2+) indicator) was shifted in the presence of EP at concentrations of ≥7 mmol/L. Furthermore, EP markedly suppressed the A23187-induced intracellular Ca(2+) surge in BV2 cells and, under this condition, A23187-induced activations of Ca(2+)-mediated kinases (protein kinase Cα and calcium/calmodulin-dependent protein kinase IV), HMGB1 phosphorylation and subsequent secretion of HMGB1 also were suppressed. (A23187 is a calcium ionophore and BV2 cells are a microglia cell line.) Moreover, the above-mentioned EP-mediated effects were obtained independent of cell death or survival, which suggests that they are direct effects of EP. Together, these results indicate that EP directly chelates Ca(2+), and that it is, at least in part, responsible for the suppression of HMGB1 release by EP.

Citing Articles

Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights.

Li X, Zhao H Exp Hematol Oncol. 2025; 14(1):12.

PMID: 39893499 PMC: 11786567. DOI: 10.1186/s40164-025-00603-0.


Emerging Roles of High-mobility Group Box-1 in Liver Disease.

Wang L, Dong Z, Zhang Y, Peng L J Clin Transl Hepatol. 2024; 12(12):1043-1056.

PMID: 39649031 PMC: 11622203. DOI: 10.14218/JCTH.2024.00317.


HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage.

Yuan J, Guo L, Ma J, Zhang H, Xiao M, Li N Cell Biol Toxicol. 2024; 40(1):55.

PMID: 39008169 PMC: 11249443. DOI: 10.1007/s10565-024-09893-2.


High mobility group box-1: a potential therapeutic target for allergic rhinitis.

Wu S, Yu Y, Zheng Z, Cheng Q Eur J Med Res. 2023; 28(1):430.

PMID: 37828579 PMC: 10571310. DOI: 10.1186/s40001-023-01412-z.


Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease.

Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P Int J Biol Sci. 2023; 19(15):5020-5035.

PMID: 37781525 PMC: 10539693. DOI: 10.7150/ijbs.87964.


References
1.
Hoppe G, Talcott K, Bhattacharya S, Crabb J, Sears J . Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res. 2006; 312(18):3526-38. DOI: 10.1016/j.yexcr.2006.07.020. View

2.
Wang Q, Ding Q, Zhou Y, Gou X, Hou L, Chen S . Ethyl pyruvate attenuates spinal cord ischemic injury with a wide therapeutic window through inhibiting high-mobility group box 1 release in rabbits. Anesthesiology. 2009; 110(6):1279-86. DOI: 10.1097/ALN.0b013e3181a160d6. View

3.
Yang R, Uchiyama T, Watkins S, Han X, Fink M . Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock. 2004; 22(4):369-75. DOI: 10.1097/01.shk.0000140659.71121.04. View

4.
Kim H, Cho I, Kim J, Shin Y, Jeon J, Kim Y . Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med. 2008; 45(7):950-63. DOI: 10.1016/j.freeradbiomed.2008.06.009. View

5.
Yu Y, Kim J, Lee K, Kim S, Han P, Lee J . Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke. 2005; 36(10):2238-43. DOI: 10.1161/01.STR.0000181779.83472.35. View